Rani Therapeutics (RANI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, with voting available online, by phone, mail, or virtually at the meeting.
Shareholders are encouraged to review proxy materials and vote on key proposals before the meeting date.
Voting matters and shareholder proposals
Election of seven nominees to the Board of Directors to serve until the 2027 Annual Meeting.
Ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Seven director nominees listed: Talat Imran, Mir Imran, Dennis Ausiello, Lisa Rometty, Jean-Luc Butel, Abraham Bassan, and Vasudev Bailey.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Rani Therapeutics
- RT-114 shows >150% oral bioavailability; Q2 revenue up, cash at $53.4M, risks persist.RANI
Q2 2026 - Oral biologics platform shows >150% bioavailability in phase I-A, fueling major partnerships and pipeline growth.RANI
Canaccord Genuity's 46th Annual Growth Conference - Directors elected, auditor ratified, and major partnerships and clinical milestones announced.RANI
AGM 2026 - Net loss narrowed to $8.0M on $1.7M revenue, with cash runway into Q4 2027 and Nasdaq delisting risk.RANI
Q1 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance in place.RANI
Proxy filing - Chugai deal, debt repayment, and clinical progress drive strong financial and pipeline momentum.RANI
Q4 2025 - Oral dual GLP-1/GLP-2 program targets obesity with weekly dosing, Phase 1 starts in 2025.RANI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - RT-114, an oral GLP-1/GLP-2 dual agonist, targets weekly dosing and global obesity market impact.RANI
Investor Update - Strong preclinical progress, reduced net loss, and RT-114 Phase 1 trial expected mid-2025.RANI
Q4 2024